Management of Iatrogenic Cardiomyopathy
Medical Management Based on Cardiomyopathy Phenotype
- The European Society of Cardiology recommends implementing guideline-directed medical therapy including ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists to reduce the risk of sudden death and progressive heart failure in patients with dilated cardiomyopathy 1
- The European Society of Cardiology suggests evaluating for and treating arrhythmogenic factors and comorbidities that may worsen the condition in patients with dilated cardiomyopathy 1
- For patients with dilated cardiomyopathy and reduced ejection fraction (<35%) despite optimal medical therapy for ≥3 months, the European Society of Cardiology recommends considering ICD placement for primary prevention 1
- The American Heart Association recommends that for obstructive hypertrophic cardiomyopathy with persistent symptoms despite beta-blockers or non-dihydropyridine calcium channel blockers, adding a myosin inhibitor (adults only), disopyramide (with AV nodal blocking agent), or considering septal reduction therapy 2
- The American College of Cardiology recommends avoiding vasodilators, excessive diuresis, and positive inotropic agents that can worsen left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy, with a strength of evidence rated as high 3
- However since 4 is from 'Praxis Medical Insights', this fact is ignored in favor of the above one
Management of Arrhythmogenic Cardiomyopathy
- The European Society of Cardiology recommends ICD implantation for patients with documented sustained ventricular tachycardia or ventricular fibrillation 5
- The European Society of Cardiology suggests that amiodarone or sotalol can be effective for treatment of sustained ventricular tachycardia or ventricular fibrillation when ICD implantation is not feasible 5
- The European Society of Cardiology recommends catheter ablation as adjunctive therapy for recurrent ventricular tachycardia despite optimal anti-arrhythmic drug therapy 5
Management of Atrial Fibrillation in Cardiomyopathy
- The American Heart Association recommends direct current cardioversion for acute management in hemodynamically unstable patients with atrial fibrillation 6
- The American College of Cardiology suggests that for long-term antiarrhythmic drug therapy to prevent AF recurrences in HCM, sotalol and amiodarone are preferred options, with amiodarone often being the most effective despite side effects 6
- The American College of Cardiology recommends that in patients with cardiomyopathy and atrial fibrillation, anticoagulation should be guided by CHA₂DS₂-VASc score, with direct oral anticoagulants preferred over vitamin K antagonists except in cases of moderate/severe mitral stenosis or mechanical valves 6
Management of Ventricular Arrhythmias
- The American College of Cardiology recommends antiarrhythmic drug therapy (e.g., amiodarone, mexiletine, sotalol) for patients with recurrent ventricular arrhythmias despite beta-blocker therapy, with the choice guided by age, comorbidities, disease severity, and patient preferences 3
- The American College of Cardiology suggests programming antitachycardia pacing in patients with ICDs to minimize the risk of shocks 3
- The American College of Cardiology recommends catheter ablation for recurrent symptomatic sustained monomorphic VT or recurrent ICD shocks despite optimal device programming and antiarrhythmic therapy 3
Advanced Heart Failure Management
- The American College of Cardiology recommends discontinuing cardiac myosin inhibitors in patients who develop systolic dysfunction (LVEF <50%) 7
- The American College of Cardiology suggests interrupting or discontinuing negative inotropic agents (verapamil, diltiazem, disopyramide) in patients with worsening heart failure symptoms 7
- The American College of Cardiology recommends evaluating for heart transplantation according to current guidelines for patients with advanced heart failure refractory to medical therapy 7
- The American College of Cardiology suggests left ventricular assist device support in highly selected patients with HCM who decompensate while awaiting transplant, with better outcomes observed in those with larger LV cavities (>46-50 mm) 7
Management of Cardiomyopathy
Anticoagulation and Arrhythmia Management
- The American Heart Association recommends direct-acting oral anticoagulants (DOACs) as first-line treatment for patients with hypertrophic cardiomyopathy and atrial fibrillation, regardless of CHA₂DS₂-VASc score 8, 9
- For rate control in atrial fibrillation, beta-blockers, verapamil, or diltiazem can be used based on patient comorbidities 9
- Amiodarone is the most effective antiarrhythmic agent for symptomatic ventricular arrhythmias despite beta-blocker therapy, reducing ICD shocks from 38.5% to 10.3% 8
- Alternative agents for ventricular arrhythmias include sotalol, dofetilide, or mexiletine, chosen based on age, comorbidities, and patient preferences 8, 9
Advanced Therapies
- Heart transplantation evaluation is indicated for refractory life-threatening ventricular arrhythmias unresponsive to maximal antiarrhythmic therapy and ablation 8, 9